Core Insights - Oncolytics Biotech Inc. will host a conference call and webcast on May 14, 2025, at 4:30 p.m. ET to discuss corporate updates and Q1 2025 financial results [1][2] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent [3] - Pelareorep has shown promising results in randomized Phase 2 studies for metastatic breast cancer and Phase 1 and 2 studies for pancreatic cancer [3] - The drug induces anti-cancer immune responses and transforms "cold" tumors into "hot" tumors, enhancing treatment efficacy through both innate and adaptive immune responses [3] Clinical Development - Oncolytics is conducting and planning combination clinical trials with pelareorep for various solid and hematological malignancies [4] - The company is advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [4]